ArticleThe Journal of cell biology2000
DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis.
Article in The Journal of cell biology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 104 citations in OpenAlex.
- Effects of the FHL2 gene on the development of subcutaneous and intramuscular adipocytes in goats.BMC genomics · 2024Article
- The roles of FHL2 in cancer.Clinical and experimental medicine · 2023Review
- FHL2 anchors mitochondria to actin and adapts mitochondrial dynamics to glucose supply.The Journal of cell biology · 2021Article
- The titin N2B and N2A regions: biomechanical and metabolic signaling hubs in cross-striated muscles.Biophysical reviews · 2021Review
- Cardiac sarcomere mechanics in health and disease.Biophysical reviews · 2021Review
- c-Abl kinase regulates cell proliferation and ionizing radiation-induced G2/M arrest via phosphorylation of FHL2.FEBS open bio · 2021Article
- Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.Cancer biology & medicine · 2020Review
- iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- RBM20, a potential target for treatment of cardiomyopathy via titin isoform switching.Biophysical reviews · 2018Review
- A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity.Nature communications · 2017Article
- FOXK1 interaction with FHL2 promotes proliferation, invasion and metastasis in colorectal cancer.Oncogenesis · 2016Article
- Review
- The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.Frontiers in oncology · 2015Review
- Transcriptional regulation of the tumor suppressor FHL2 by p53 in human kidney and liver cells.PloS one · 2014Article
- FHL2 expression and variants in hypertrophic cardiomyopathy.Basic research in cardiology · 2014Article
- Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer.British journal of cancer · 2013Article
- FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo.PloS one · 2013Article
- FHL2 binds calcineurin and represses pathological cardiac growth.Molecular and cellular biology · 2012Article
- FHL2 interacts with CALM and is highly expressed in acute erythroid leukemia.Blood cancer journal · 2011Article
- Epigenetic silencing of a proapoptotic cell adhesion molecule, the immunoglobulin superfamily member IGSF4, by promoter CpG methylation protects Hodgkin lymphoma cells from apoptosis.The American journal of pathology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DRAL is a four and a half LIM domain protein identified because of its differential expression between normal human myoblasts and the malignant counterparts, rhabdomyosarcoma cells. In the current study, we demonstrate that transcription of the DRAL gene can be stimulated by p53, since transient expression of functional p53 in rhabdomyosarcoma cells as well as stimulation of endogenous p53 by ionizing radiation in wild-type cells enhances DRAL mRNA levels. In support of these observations, five potential p53 target sites could be identified in the promoter region of the human DRAL gene. To obtain insight into the possible functions of DRAL, ectopic expression experiments were performed. Interestingly, DRAL expression efficiently triggered apoptosis in three cell lines of different origin to the extent that no cells could be generated that stably overexpressed this protein. However, transient transfection experiments as well as immunofluorescence staining of the endogenous protein allowed for the localization of DRAL in different cellular compartments, namely cytoplasm, nucleus, focal contacts, as well as Z-discs and to a lesser extent the M-bands in cardiac myofibrils. These data suggest that downregulation of DRAL might be involved in tumor development. Furthermore, DRAL expression might be important for heart function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.